Dynavax Technologies

Dynavax is a commercial-stage biopharmaceutical company developing and commercializing novel vaccines. The company's first commercial product, HEPLISAV-B®, has been approved in the United States and the European Union for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults aged 18 years and older. Dynavax is also advancing CpG 1018TM adjuvant as a premier vaccine adjuvant through research collaborations and partnerships.